Trial Profile
An Open-Label, Single-Arm, Multiple Center Extension Study to Evaluate One Year of Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer With YONSA™ 500 mg (4 x 125 mg qd) With Methylprednisolone (4 mg Bid)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Nov 2021
Price :
$35
*
At a glance
- Drugs Abiraterone acetate (Primary) ; Methylprednisolone (Primary)
- Indications Prostate cancer
- Focus Adverse reactions
- Acronyms STAAR-E
- Sponsors Churchill Pharmaceuticals; Sun Pharmaceutical Industries
- 02 Jul 2019 Status changed from recruiting to completed.
- 10 Feb 2018 Results (n=20) presented at the 2018 Genitourinary Cancers Symposium.
- 06 Feb 2018 According to a Churchill Pharmaceuticals media release, the results of the study will be presented at the 2018 American Society of Clinical Oncology, Genitourinary Cancers Symposium (ASCO GU).